Business
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis-- FREMONT,
About this update from Ardelyx, Inc.
[{"type":"text","content":"--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis--\n\n\nFREMONT, Calif., Oct. 12, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that five abstracts on tenapanor have been accepted for presentation at Kidney Week 2020, the American Society of Nephrology's (ASN) Annual Meeting, to be held October 22-25, 2020. Tenapanor, which was discovered and developed by Ardelyx, is a first-in-class therapy under review for potential marketing approval by the U.S. Food and Drug Administration (FDA) for the control of serum phosphorus in adult patients with CKD on dialysis.\n\n \n \n \n \n \n \n\n \nThree poster presentations highlight data from several Phase 3 trials in the U.S., including the BLOCK, AMPLIFY and PHREEDOM studies. Additionally, the company's partner for tenapanor in Japan, Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151), will present results from two Phase 2 studies evaluating the efficacy and safety of tenapanor in Japanese patients on hemodialysis. \nInformation regarding ASN's Kidney Week, including copies of presentation abstracts, can be found at https://www.asn-online.org/education/kidneyweek.\nArdelyx Poster Presentations: \nTitle:\nLong-term Safety and Efficacy of Tenapanor for the Control of Serum Phosphorus in Patients with CKD on Dialysis\nAbstract Number:\n3450189\nePoster Number:\nPO0384\nDate/Time:\nThursday, October 22, 10:00 a.m. EDT\nTitle:\nEfficacy of Tenapanor for the Control of Serum Phosphorus in Patients with CKD on Dialysis: Novel Mechanism of Action Allows for Both Monotherapy and Dual Mechanism Approach\nAbstract Number:\n3450673\nePoster Number:\nPO0374\nDate/Time:\nThursday, October 22, 10:00 a.m. EDT\nTitle:\nTolerability of Tenapanor, an Investigational, First-in-Class, Non-Binder Therapy for the Control of Serum Phosphorus in Patients with CKD on Dialysis\nAbstract Number:\n3450921\nePoster Number:\nPO0376\nDate/Time:\nThursday, October 22, 10:00 a.m. EDT\nKyowa Kirin Poster Presentations:\nTitle:\nDose-Response Efficacy and Tolerability of Tenapanor on Hyperphosphatemia in Japanese Hemodialysis Patients: Results of a Randomized Phase 2 Stud...